Niva Bupa Health

Why is Niva Bupa Health Insurance Company Ltd falling/rising?

As of 15-Jul, Niva Bupa Health Insurance Company Ltd's stock price is rising to Rs 88.36, reflecting a 2.59% increase. The stock shows strong upward momentum supported by significant investor participation and positive long-term fundamentals.

As of 15-Jul, Niva Bupa Health Insurance Company Ltd's stock price is rising, currently at Rs 88.36, reflecting a change of Rs 2.23 or 2.59%. The stock has outperformed the sector by 2.05% today and has shown a significant increase in investor participation, with a delivery volume that rose by 211.38% compared to the 5-day average. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend.<BR><BR>In terms of performance over different periods, the stock has increased by 4.15% over the past week and 5.88% over the past month, while year-to-date, it has risen by 17.03%. This positive momentum is supported by strong long-term fundamentals, including a 24.47% compound annual growth rate (CAGR) in operating profits and a 27.50% annual growth rate in net sales. The company recently reported its highest quarterly net sales at Rs 2,138.56 crore, which has contributed to the positive sentiment surrounding the stock.<BR><BR>Moreover, the increase in institutional holdings to 27.09% suggests confidence from larger investors, who typically have more resources to analyze company fundamentals. This further supports the stock's rising trend. Overall, the combination of strong financial performance, increased investor interest, and favorable technical indicators are driving the rise in Niva Bupa Health Insurance Company Ltd's stock price.

Which are the latest news on Niva Bupa Health?

Should I buy, sell or hold Niva Bupa Health Insurance Company Ltd?

What does Niva Bupa Health do?

Niva Bupa Health Insurance Company Ltd, originally Max Bupa, operates in the insurance sector and reported net sales of ₹1,972 Cr and a net profit of ₹345 Cr for Q1 2026, with a market cap of ₹15,497 Cr. Key metrics include a P/E ratio of 118.00 and a debt-equity ratio of 0.07.

Overview:<BR>Niva Bupa Health Insurance Company Ltd operates in the insurance industry and is categorized as a small-cap company.<BR><BR>History:<BR>Niva Bupa Health Insurance Company Limited was originally incorporated as Max Bupa Health Insurance Limited in 2008. The company was granted its Certificate for Commencement of Business on December 23, 2008. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,972 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 345 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 15,497 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 118.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.07 <BR>Return on Equity: 3.44% <BR>Price to Book: 4.07 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Niva Bupa Health?

As of 10th June, Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,497.00 Cr and reported net sales of 6067.57 Cr and a net profit of 130.78 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Niva Bupa Health Insurance Company Ltd has a market capitalization of 15,497.00 Cr, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 6067.57 Cr, while the sum of Net Profit for the same period is 130.78 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 3,776.22 Cr, and Total Assets amount to 9,760.16 Cr.

Who are the peers of the Niva Bupa Health?

Niva Bupa Health's peers include HDFC Life, ICICI Lombard, Max Financial, and Star Health, among others. It shows good growth and average management risk, with a 1-year return of 1.95%, lower than Star Health's 12.98% but higher than Medi Assist's -29.51%.

Peers: The peers of Niva Bupa Health are HDFC Life Insur., ICICI Lombard, ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, Go Digit General, New India Assura, and Medi Assist Ser.<BR><BR>Quality Snapshot: Excellent management risk is observed at ICICI Lombard and Go Digit General, while Average management risk is found at HDFC Life Insur., ICICI Pru Life, General Insuranc, Max Financial, Star Health Insu, and Niva Bupa Health, and the rest. Good management risk is noted at Medi Assist Ser. Below Average management risk is present at New India Assura. In terms of Growth, Good growth is seen at Niva Bupa Health and Go Digit General, while Average growth is found at HDFC Life Insur., ICICI Lombard, General Insuranc, and Medi Assist Ser., and the rest. Below Average growth is noted at ICICI Pru Life, Max Financial, and Star Health Insu, along with New India Assura. Excellent capital structure is observed across all peers.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Star Health Insu at 12.98%, while the peer with the lowest is Medi Assist Ser. at -29.51%. Niva Bupa Health's 1-year return is 1.95%, which is higher than Medi Assist Ser. but lower than Star Health Insu. Additionally, the peers with negative six-month returns include Medi Assist Ser., Max Financial, and New India Assura.

Are Niva Bupa Health Insurance Company Ltd latest results good or bad?

Niva Bupa Health Insurance Company's Q4 FY26 results show strong growth with a net profit increase of 67.48% and revenue up 29.10%. However, concerns about earnings volatility and underperformance compared to the sector suggest caution for investors regarding future stability.

Niva Bupa Health Insurance Company Ltd's latest results for Q4 FY26 present a mixed picture. On the positive side, the company reported a net profit of ₹345.13 crores, a significant increase from ₹206.08 crores in the same quarter last year, reflecting a year-on-year growth of 67.48%. Additionally, revenue grew by 29.10% year-on-year, reaching ₹1,971.95 crores, and the operating margin improved to 18.52%, up from 16.41% in Q4 FY25.<BR><BR>However, these impressive figures are overshadowed by a troubling pattern of extreme earnings volatility throughout FY26. The company experienced consecutive quarterly losses in the first three quarters before this sudden profitability in Q4, raising concerns about the sustainability of its earnings. Furthermore, Niva Bupa's stock has underperformed compared to the broader insurance sector, declining 6.99% over the past year while the sector gained 17.75%.<BR><BR>In summary, while the latest quarterly results show strong growth and a turnaround in profitability, the underlying volatility and past performance issues suggest caution for investors regarding the company's future consistency and stability.

When is the next results date for Niva Bupa Health Insurance Company Ltd?

The next results date for Niva Bupa Health Insurance Company Ltd is January 29, 2026.

The next results date for Niva Bupa Health Insurance Company Ltd is scheduled for January 29, 2026.

Is Niva Bupa Health technically bullish or bearish?

As of November 28, 2025, Niva Bupa Health's technical stance is bearish due to negative indicators like a bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory.

As of 28 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Niva Bupa Health is bearish, with a moderate strength. Key indicators driving this stance include the bearish MACD on the weekly timeframe, bearish signals from Bollinger Bands and moving averages on the daily timeframe, and a bearish KST on the weekly. Although the Dow Theory indicates a mildly bullish signal on the weekly, it is outweighed by the overall bearish indicators. The stock has underperformed against the Sensex year-to-date and over the past year, further supporting the bearish outlook.

How has been the historical performance of Niva Bupa Health?

Niva Bupa Health experienced significant growth from March 2024 to March 2025, with net sales rising to 4,894.46 Cr and profit after tax increasing to 213.52 Cr, while total assets grew to 9,760.16 Cr. The company improved its operating profit margin to 1.19% and enhanced cash flow from operating activities to 1,654.00 Cr.

Answer:<BR>The historical performance of Niva Bupa Health shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Niva Bupa Health's net sales increased from 3,811.25 Cr in March 2024 to 4,894.46 Cr in March 2025, while other operating income rose from 304.22 Cr to 479.82 Cr, leading to a total operating income of 5,374.28 Cr, up from 4,115.47 Cr. Total expenditure, excluding depreciation, also increased to 5,316.18 Cr from 4,254.40 Cr, with employee costs rising slightly and manufacturing expenses significantly increasing from 3,000.37 Cr to 4,061.10 Cr. The company turned around its operating profit, achieving 213.52 Cr in March 2025 compared to 81.85 Cr in March 2024, with a notable improvement in operating profit margin from -3.65% to 1.19%. Profit after tax also saw a substantial increase from 81.85 Cr to 213.52 Cr, resulting in a PAT margin growth from 2.15% to 4.36%. On the balance sheet, total assets grew from 6,191.86 Cr to 9,760.16 Cr, driven by an increase in non-current investments from 5,458.23 Cr to 8,175.08 Cr. Shareholder's funds rose significantly from 2,982.62 Cr to 3,776.22 Cr, while total liabilities increased to 9,760.16 Cr from 6,191.86 Cr. Cash flow from operating activities improved to 1,654.00 Cr from 812.00 Cr, although cash flow from investing activities worsened to -2,347.00 Cr from -1,881.00 Cr. The closing cash and cash equivalents increased to 220.00 Cr from 142.00 Cr, reflecting a positive cash flow trend.

Is Niva Bupa Health overvalued or undervalued?

As of November 27, 2024, Niva Bupa Health is considered very expensive and overvalued, with a PE ratio of 71.14 and significant underperformance at -0.62% year-to-date compared to the Sensex's 5.54%.

As of 27 November 2024, the valuation grade for Niva Bupa Health has moved from does not qualify to very expensive. The company is currently considered overvalued, with a PE ratio of 71.14, an EV to EBITDA ratio of 263.82, and a Price to Book Value of 7.37. These metrics significantly exceed those of its peers, such as Life Insurance with a PE ratio of 12.54 and Bajaj Finance Ltd. at 35.01, indicating a stark contrast in valuation.<BR><BR>In comparison to the broader market, Niva Bupa Health has underperformed, with a year-to-date return of -0.62% against the Sensex's 5.54%. This underperformance, coupled with its high valuation ratios, reinforces the conclusion that the company is overvalued in the current market environment.

Who are the top shareholders of the Niva Bupa Health?

The top shareholders of Niva Bupa Health are Bupa Singapore Holdings Pte Ltd with 55.98%, followed by foreign institutional investors at 8.9%, mutual funds at 2.68%, and individual investors at 4.23%. There are no pledged promoter holdings, reflecting strong promoter commitment.

The top shareholders of Niva Bupa Health include Bupa Singapore Holdings Pte Ltd, which holds a significant 55.98% of the company. The majority of the remaining shares are held by mutual funds, which account for 2.68% across 14 schemes, and foreign institutional investors (FIIs), who hold 8.9% through 42 different entities. Additionally, individual investors collectively own 4.23% of the shares. Notably, there are no pledged promoter holdings, indicating a strong commitment from the promoters.

Has Niva Bupa Health declared dividend?

No Dividend History Available